Dyadic International wouldn't have made the list the year before but did in 2005 after changing its focus.
Donn Szaro
We believe even more so that at least the U.S. Public [biotech] sector will be profitable before the end of this decade.
end public
The global biotechnology industry's revenues are growing at strong rates, product approvals are bringing innovative drugs to market, and the long- elusive goal of profitability is quickly approaching.
drugs growing global strong goal market
Since our first report 20 years ago, we've seen historic scientific advances and dramatic changes in market conditions combine to produce a rapidly maturing industry. Companies from around the globe are pioneering new technologies, platforms, industry segments, and business models.
business market industry
Deals were a key driver in Asia-Pacific, where companies formed partnerships to position themselves in an environment characterized by brisk growth, increasing competition, and sweeping regulatory changes. There was unprecedented consolidation among Japan's largest pharmaceutical companies, as well as noteworthy deals across the region.
competition environment key growth
focus changing made
You must log in to post a comment.
There are no comments yet.